CAM
AVIR icon

Costello Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Costello Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$300 – 182
2023
Q3 		$300 Hold
100
– – ﹤0.01% 193
2023
Q2 		$374 Hold
100
– – ﹤0.01% 192
2023
Q1 		$335 Hold
100
– – ﹤0.01% 210
2022
Q4 		$481 Hold
100
– – ﹤0.01% 208
2022
Q3 		$1K Hold
100
– – ﹤0.01% 209
2022
Q2 		$1K Hold
100
– – ﹤0.01% 217
2022
Q1 		$1K Hold
100
– – ﹤0.01% 228
2021
Q4 		$1K Sell
100
-65
-39% -$1.01K ﹤0.01% 231
2021
Q3 		$6K Buy
+165
New +$4.58K ﹤0.01% 185

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Costello Asset Management's AVIR Position: Q4 2023 in Review

Costello Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 100 shares — an estimated $300 sold.

Costello Asset Management first reported a position in AVIR in Q3 2021 and held it in 9 quarters. The position peaked at $6K in Q3 2021. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • Costello Asset Management reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Costello Asset Management sold 100 Atea Pharmaceuticals shares in Q4 2023, an estimated $300.
  • Costello Asset Management first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 9 quarters.
  • Costello Asset Management's Atea Pharmaceuticals position peaked at $6K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Costello Asset Management's 13F filing for Q4 2023, filed 29 Jan 2024.